Medical Specialty >> Gynecology
Obesity Raises Odds for Many Common Cancers
7:46 PM CDT.
By Steven Reinberg HealthDay Reporter Read article
- Women Get Help Later Than Men When Heart Attack Strikes
- Pregnancy Within 1 Year of Weight-Loss Surgery Carries Added Risks
- Heart Risk Factors Show Up Earlier in U.S. Black Women
- A Vitamin Could Be Key to Women’s Pain After Knee Replacement
JOURNAL UPDATE
2001 to 2018 Saw Increase in Estimated Prevalence of IBD in Seniors
8:57 PM CDT.Increase higher among non-Hispanic Blacks, while prevalence was consistently highest for non-Hispanic…
- Black Women More Likely to Have Idiopathic Intracranial HTN
- Mental Health Poor for 11 Percent of U.K. Adults During COVID-19
- Sleep Medications Do Not Improve Sleep Disturbance in Women
MONTHLY JOURNAL SUMMARY
September 2020 Briefing - OBGYN & Women’s Health
October 01, 2020. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Immunotherapy with Checkpoint Inhibitors in Triple Negative Breast Cancer (TNBC)
Karima Oualla, MD.
Dr. Karima Oualla discusses recent advances on the use of checkpoint inhibitors in the treatment of triple negative breast cancer (TNBC). Dr. Oualla is an International expert in breast cancer and is the primary author of the manuscript entitled "Novel therapeutic strategies in the treatment of triple-negative…
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Characterization of patients with ovarian carcinoma who respond to the PARP inhibitor rucaparib
Elizabeth M. Swisher, MD.
Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity…
MEDICAL FOCUS
Breast cancer
By Tamer M. Fouad, M.D. Breast cancer is a cancer that starts in the cells of the breast. Worldwide, breast cancer is the second most common type of cancer after lung cancer (11.9%…
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By namabcAs I understand, this is a great step of development that we can use to save many people from horrible diseases. and i also hope Dr.Lain and your partners…
